Skip to main content
← Companies
CLDX

Celldex Therapeutics, Inc.

Data as of Sep 17, 2026
CLDX
CIK 744218

Lobbying

$350,000 in reported federal lobbying spend across 7 quarterly filings, most recently Jul 20, 2026. Amounts are the sums companies and their registrants report on Lobbying Disclosure Act filings; a filing that covers several issues counts its full amount under each.

Spend by issue

  • Health Issues$270K5 filings

Latest filings, Apr 2025 onward

FiledRegistrant and subjectAmount
Jul 20, 2026
AKIN GUMP STRAUSS HAUER & FELD for CELLDEX THERAPEUTICS INC.
Health Issues Issues related to mast cell conditions and therapies; Issues related to drug development and biopharma ecosystem.
$90,000
Apr 20, 2026
AKIN GUMP STRAUSS HAUER & FELD for CELLDEX THERAPEUTICS INC.
Unspecified
$60,000
Jan 20, 2026
AKIN GUMP STRAUSS HAUER & FELD for CELLDEX THERAPEUTICS INC.
Health Issues Issues related to NIH-funded research; Issues related to mast cell conditions and therapies.
$60,000
Oct 20, 2025
AKIN GUMP STRAUSS HAUER & FELD for CELLDEX THERAPEUTICS INC.
Health Issues Issues related to NIH-funded eosinophilic gastrointestinal disease research; Issues related to mast cell conditions and therapies.
$60,000
Jul 21, 2025
AKIN GUMP STRAUSS HAUER & FELD for CELLDEX THERAPEUTICS INC.
Health Issues Issues related to NIH-funded eosinophilic gastrointestinal disease research.
$60,000
Apr 21, 2025
AKIN GUMP STRAUSS HAUER & FELD for CELLDEX THERAPEUTICS INC.
Unspecified
$20,000

Data: Quiver Quantitative, FEC, Senate Lobbying Disclosure Act filings, USAspending, congressional periodic transaction reports. Records are matched to Celldex Therapeutics, Inc. through its SEC registration (CIK 744218) and tickers CLDX.

As of: lobbying filings through Jul 20, 2026. Snapshot rebuilt Sep 17, 2026.

Holdings values are estimates from disclosed ranges. Donation coverage for a cycle begins with the first month loaded, so earlier months may still be missing.